Who are Greenwich LifeSciences, Inc.'s main suppliers?

Greenwich LifeSciences, Inc. (GLSI) key suppliers include: HJF, THIRD-PARTY-CONTRACT-MANUFACTURERS, AstraZeneca PLC, AstraZeneca PLC, Gilead Sciences, Inc. and 5 more. View the full supplier network at chainsifter.com/chain/GLSI.

Who are Greenwich LifeSciences, Inc.'s major customers?

Greenwich LifeSciences, Inc. (GLSI) key customers include: AEGIS-CAPITAL-CORP. View the full customer network at chainsifter.com/chain/GLSI.

What sector is Greenwich LifeSciences, Inc. in?

Greenwich LifeSciences, Inc. (GLSI) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Greenwich LifeSciences, Inc. Suppliers, Customers & Supply Chain (GLSI)

10Suppliers

1Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Greenwich LifeSciences, Inc. (GLSI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

13Total relationships

4Distinct source URLs

4High confidence

0.768Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Greenwich LifeSciences, Inc. Suppliers

Ticker	Name	Confidence	Evidence
HJF	HJF	90%	We currently are dependent on a license from HJF for technologies relating to our product candidate.
THIRD-PARTY-CONTRACT-MANUFACTURERS	THIRD-PARTY-CONTRACT-MANUFACTURERS	90%	The Company currently depends on third-party contract manufacturers for all required raw materials, active pharmaceutical ingredients, and finished product candidate for the Company’s clinical trials.
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from GLSI graph: duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adve…
AZN	AstraZeneca PLC	72%	duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adverse events or chance findings that may only be detected once the product is admin…
GILD	Gilead Sciences, Inc.	72%	duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adverse events or chance findings that may only be detected once the product is admin…
GILD	Gilead Sciences, Inc.	72%	Reciprocal relationship from GILD graph: Reciprocal relationship from GLSI graph: Reciprocal relationship from GILD graph: Reciprocal relationship from GLSI graph: duct candidate and the average expo…
JNJ	Johnson & Johnson	72%	duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adverse events or chance findings that may only be detected once the product is admin…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from GLSI graph: duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adve…
MRK	Merck & Co., Inc.	72%	duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adverse events or chance findings that may only be detected once the product is admin…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from GLSI graph: Reciprocal relationship from MRK graph: Reciprocal relationship from GLSI graph: Reciprocal relationship from MRK grap…

Greenwich LifeSciences, Inc. Customers

Ticker	Name	Confidence	Evidence
AEGIS-CAPITAL-CORP	AEGIS-CAPITAL-CORP	62%	. F- 11 Table of Contents GREENWICH LIFESCIENCES, INC. NOTES TO FINANCIAL STATEMENTS Warrants Prior to the IPO, there were no outstanding warrants to purchase shares of common stock accounted for as …

Greenwich LifeSciences, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
GLSI-DEBT-9804	Warrants outstanding: 8012684	90%	xbrl warrant detail from xbrl 2025-09-30.

Greenwich LifeSciences, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Greenwich LifeSciences, Inc..

Greenwich LifeSciences, Inc. Ownership

Holder	Name	Confidence	Evidence
GLSI-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 64 tracked holders.

Greenwich LifeSciences, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
JNJ	Johnson & Johnson	100.00	1	['supplier']
MRK	Merck & Co., Inc.	100.00	1	['supplier']
GILD	Gilead Sciences, Inc.	100.00	1	['supplier']
AZN	AstraZeneca PLC	100.00	1	['supplier']
CEROW	CERO THERAPEUTICS HOLDINGS, INC.	50.00	2
AORT	Artivion, Inc.	50.00	2
CTNM	Contineum Therapeutics, Inc.	50.00	2
DEO	Diageo plc	50.00	2
CYCN	Cyclerion Therapeutics, Inc.	50.00	2
EXOZ	eXoZymes, Inc.	50.00	2
BNBX	BNB Plus Corp.	50.00	2
CYTOF	Altamira Therapeutics Ltd.	50.00	2
ENGNW	enGene Therapeutics Inc.	50.00	2
CANF	Can-Fite BioPharma Ltd.	50.00	2
AVIR	Atea Pharmaceuticals, Inc.	50.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	50.00	2
FCX	Freeport-McMoRan Inc.	50.00	2
IMMP	Immutep Limited	50.00	2
CYTK	Cytokinetics, Incorporated	50.00	2
DKS	DICK'S Sporting Goods, Inc.	50.00	2

Greenwich LifeSciences, Inc. Supply Chain